[Prevention of respiratory syncytial virus infections with palivizumab].
Barneenheten Helse Stavanger Postboks 8100 4068 Stavanger. oykn@sir.no
Bente Brannsether
BB
Ellingsen
Sonja Amdal
SA
Aase
Knut
K
Øymar
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D001997:Bronchopulmonary Dysplasia / Q000150:complications / Q000188:drug therapy / Q000821:virology; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy / Q000821:virology; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000517:prevention & control*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab